Joint Meeting - Nonprescription Drugs Advisory Committee &
Pulmonary - Allergy Drugs Advisory Committee
May 11, 2001
Petition 98P-0610/CP1 - submitted
by Blue Cross of California requesting
fexofenadine hydrochloride, loratadine and cetirizine hydrocholoride be switched
to OTC status
Slides
Welcome and Introduction to Today's Issues, Charles Ganley, MD, FDA ppt htm
Petition to Convert Claritin, Allegra and Zyrtec to OTC Status, Robert Seidman, PharmD, MPH, WellPoint Health Networks ppt htm
non-Sedating Antihistamines RX-to-OTC Switch, Francois Nader, MD, Aventis Pharmaceuticals, Inc ppt htm
Response to Petition, Robert J Spiegel, MD, Schering Plough ppt htm
OTC Considerations, Cazemiro R Martin, FDA ppt htm
Clinical Perspective on Citizen Petition, Robert J Meyer MD, FDA ppt htm
Cost-effectiveness of converting non-sedating antihistamines from prescription to over-the-counter status, Michael B Nichol PhD ppt htm